Abstract
Monoamine oxidase (MAO) inhibitors continue to be used for treatment of a number of psychiatric and neurologic disorders. In recent years, inhibitors of MAO and other amine oxidases have received considerable attention because of their neuroprotective and neurorescue effects in such models as oxygen-glucose deprivation in vitro, thiamine deficiency, NMDA-instigated excitotoxicity, free radical-mediated oxidative stress, cerebral ischemia, and experimental models of Alzheimers and Parkinsons Diseases. This review focuses on the MAO inhibitors l-deprenyl, tranylcypromine and phenelzine and the possible mechanisms underlying their neuroprotective actions. In addition, there is a discussion of analogs of phenelzine and l-deprenyl as inhibitors of other amine oxidases, including semicarbazide-sensitive amine oxidase (SSAO), and their possible involvement in neuroprotection.
Keywords: neuroprotection, neurorescue, l-deprenyl, amine oxidase, semicarbazide-sensitive amine oxidase, phenelzine, phenylethylidenehydrazine
Current Neuropharmacology
Title: Amine Oxidase Inhibitors and Development of Neuroprotective Drugs
Volume: 2 Issue: 2
Author(s): Bernard N. Sowa, Kathryn G. Todd, A. M. I Tanay, Andrew Holt and Glen B. Baker
Affiliation:
- Department of Psychiatry, 1E7.31 Mackenzie Centre, University of Alberta, Edmonton, AB, Canada T6G 2B7.,Canada
Keywords: neuroprotection, neurorescue, l-deprenyl, amine oxidase, semicarbazide-sensitive amine oxidase, phenelzine, phenylethylidenehydrazine
Abstract: Monoamine oxidase (MAO) inhibitors continue to be used for treatment of a number of psychiatric and neurologic disorders. In recent years, inhibitors of MAO and other amine oxidases have received considerable attention because of their neuroprotective and neurorescue effects in such models as oxygen-glucose deprivation in vitro, thiamine deficiency, NMDA-instigated excitotoxicity, free radical-mediated oxidative stress, cerebral ischemia, and experimental models of Alzheimers and Parkinsons Diseases. This review focuses on the MAO inhibitors l-deprenyl, tranylcypromine and phenelzine and the possible mechanisms underlying their neuroprotective actions. In addition, there is a discussion of analogs of phenelzine and l-deprenyl as inhibitors of other amine oxidases, including semicarbazide-sensitive amine oxidase (SSAO), and their possible involvement in neuroprotection.
Export Options
About this article
Cite this article as:
Sowa N. Bernard, Todd G. Kathryn, I Tanay M. A., Holt Andrew and Baker B. Glen, Amine Oxidase Inhibitors and Development of Neuroprotective Drugs, Current Neuropharmacology 2004; 2(2) . https://dx.doi.org/10.2174/1570159043476800
DOI https://dx.doi.org/10.2174/1570159043476800 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Polyphenols from Red Wine Modulate Immune Responsiveness: Biological and Clinical Significance
Current Pharmaceutical Design Amlodipine (150 mg) Poisoning: A Case Study
Current Drug Safety Ethosomes as Novel Vesicular Carrier: An Overview of the Principle, Preparation and its Applications
Current Drug Delivery Transformation of UPLC-MS Data Overcomes Extreme Variability in Urine Concentration and Metabolite Fold Change
Current Metabolomics α-Synuclein Misfolding and Neurodegenerative Diseases
Current Protein & Peptide Science Microbial Polysaccharides and their Derivatives as Current and Prospective Pharmaceuticals
Current Pharmaceutical Design From the Oxygen to the Organ Protection: Erythropoietin as Protagonist in Internal Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry A<sub>3</sub> Adenosine Receptor: A Plausible Therapeutic Target for Cardio-Protection in Diabetes
Recent Patents on Cardiovascular Drug Discovery An Inducible Expression System for Recombinant Sca Proteins with an Autotransporter Domain from <i>Orientia Tsutsugamushi in Escherichia coli</i>
Protein & Peptide Letters Regulation of Apoptosis by Gram-Positive Bacteria: Mechanistic Diversity and Consequences for Immunity
Current Immunology Reviews (Discontinued) Thoracic Surgical Approaches in the Trauma Setting: A Basic Review
Current Respiratory Medicine Reviews Nitric Oxide and Dietary Factors: Part V Summary/Conclusion and References
Vascular Disease Prevention (Discontinued) S-Nitrosylation and Attenuation of Excessive Calcium Flux by Pentacycloundecane Derivatives
Medicinal Chemistry Non-Respiratory Manifestations of COVID-19 and Pathophysiological Evidences
New Emirates Medical Journal Design, Synthesis and Biological Evaluation of Benzopyran Derivatives as KATP Channel Openers
Letters in Drug Design & Discovery Immunonutrition in Surgical Patients
Current Drug Targets Biological Drugs in Guillain-Barré Syndrome: An Update
Current Neuropharmacology Biosafety of Adenoviral Vectors
Current Gene Therapy MDR1/P-Glycoprotein (ABCB1) as Target for RNA Interference-Mediated Reversal of Multidrug Resistance
Current Drug Targets Medication-Induced Nephrotoxicity in Older Patients
Current Drug Metabolism